Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · POLYMED

POLY MEDICUR

HealthcareHealthcare Equipment & Supplies₹16753 cr market cap
₹1670.60 ▲ +0.97% today As of 19 Nov 2026
52-week low ₹1191.1052-week high ₹2025.30

-18.3% from the 52-week high · +38.9% above the low

Poly Medicure Ltd. engages in the provision and sales of medical devices. The company is headquartered in Faridabad, Haryana. The company went IPO on 2011-12-05. The firm is primarily in the business of manufacture and sale of medical devices. The firm offers a diverse portfolio of medical devices in the product verticals of infusion therapy, oncology, anesthesia and respiratory care, covid care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others. The company supplies its products to approximately 120 countries, in Europe, Africa, Americas, Australia, and Asia. Its products include suction control valve, safety arterial cannula, VTM Kit, VLTM kit, blood collection needle with flashback, and pre-filled syringes. The firm operate nine manufacturing facilities across India, China, Egypt, and Italy. In India, it operates six manufacturing facilities, four of which are situated at Faridabad (Haryana), and one each in Jaipur (Rajasthan) and Haridwar (Uttarakhand).

The short version. POLY MEDICUR reported revenue of ₹581 crore for Sep 2026, up 30.9% from a year earlier. Net profit was ₹95 crore (up 3.3% year on year). Return on equity was 10.4% in Mar 2026. Promoter holding was 62.41% in Sep 2026, down 0.02 points over 8 quarters.

1 · The price

How has the stock traded?

POLY MEDICUR trades 18.3% below its 52-week high and 38.9% above its 52-week low.

Change over period: —

1M+6.7%
3M-6.5%
6M+13.4%
1Y-12.9%

2 · The business

Is it growing?

Sales, year on year+30.9%

Sep 2026 revenue of ₹581 cr.

Profit, year on year+3.3%

Sep 2026 net profit of ₹95 cr.

Net margin16.4%

4.3 pts lower than a year earlier.

3-year growth21.6% profit

Revenue compounded at 20.1% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue581525535494444403441424
Net profit9586667192939285
Net margin %16.416.412.414.420.723.120.820.1
EPS (₹)9.398.496.547.09.069.199.068.41

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue1875167013761115923786687611
Net profit3223392581791471369665
Net margin %17.220.318.816.115.917.314.010.7
EPS (₹)31.7833.4126.9118.6915.2814.1710.867.41

3 · The quality

How well does it turn capital into profit?

Return on equity was 10.4% in Mar 2026; debt to equity is 0.11.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %10.412.217.614.4
Return on capital %13.216.323.419.0
EBITDA margin %27.830.829.126.2
Net margin %16.119.218.015.6

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR20.1%19.9%
Profit CAGR21.6%18.9%
Debt to equity0.11
Interest cover24.1x
Current ratio3.37
P/E ratio52.8

4 · The owners

Who holds it, and are they adding?

Promoter holding62.41%

Down 0.02 pts over 8 quarters.

Foreign institutions5.35%

Down 6.98 pts over 8 quarters.

Domestic institutions15.9%

Up 4.24 pts over 8 quarters.

Mutual fund schemes78

+25 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter62.4362.4362.4362.4162.4162.4162.4162.41-0.02
FII12.3311.4611.419.779.45.915.575.35-6.98
DII11.6611.9611.7213.5413.8415.5916.0815.9+4.24
Public13.5714.1514.4414.2714.3416.0815.9416.33+2.76

Mutual fund holdings · Oct 2026

78 schemes hold this stock

53 the month before.

  • quant Small Cap Fund1.87% of NAV
  • SBI Healthcare Opportunities Fund1.53% of NAV
  • DSP Nifty Smallcap250 Quality 50 Index Fund1.44% of NAV
  • SBI MNC Fund1.42% of NAV
  • ITI Pharma and Healthcare Fund1.28% of NAV
  • Invesco India Large cap Fund1.26% of NAV
  • HSBC Midcap Fund1.07% of NAV
  • Invesco India Equity Savings Fund1.0% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for POLY MEDICUR are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about POLY MEDICUR

What is the POLY MEDICUR share price?

POLY MEDICUR (POLYMED) last closed at ₹1,670.60, up 0.97% on the day. Its 52-week range is ₹1,191.10 to ₹2,025.30.

What is the market cap of POLY MEDICUR?

POLY MEDICUR has a market capitalisation of about ₹16,753 crore. Its price-to-earnings ratio is 52.8.

How are POLY MEDICUR's latest results?

POLY MEDICUR reported revenue of ₹581 crore for Sep 2026, up 30.9% from a year earlier. Net profit was ₹95 crore (up 3.3% year on year). Return on equity was 10.4% in Mar 2026. Promoter holding was 62.41% in Sep 2026, down 0.02 points over 8 quarters.

Who owns POLY MEDICUR?

As of Sep 2026, shareholding was: Promoter 62.41%, FII 5.35%, DII 15.9%, Public 16.33%.

How many mutual funds hold POLY MEDICUR?

78 mutual fund schemes held POLY MEDICUR in October 2026. That compares with 53 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 18 Sep 2025 · Final Dividend - Rs. 3.5
  • 19 Sep 2024 · Final Dividend - Rs. 3
  • 21 Sep 2023 · Final Dividend - Rs. 3
  • 16 Sep 2022 · Final Dividend - Rs. 2.5
  • 16 Sep 2021 · Dividend - Rs. 2.5
  • 27 Feb 2020 · Interim Dividend - Rs. 2

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.